A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies — Noboru Yamamoto (2019) | RDL Network
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
Joaquı́n Mateo, David Olmos, Herlinde Dumez, Srinivasu Poondru, Nancy L. Samberg, Sharon Barr, Jan M. Van Tornout, Fei Jie, Shahneen Sandhu, Daniel S.W. Tan, Víctor Moreno, Patricia LoRusso, Stan B. Kaye, Patrick Schöffski
Christophe Massard, Jean‐Charles Soria, Alan Anthoney, Alicia M Proctor, Angela Scaburri, M. A. Pacciarini, B. Laffranchi, Cinzia Pellizzoni, Guido Guido Kroemer, Jean‐Pierre Armand, Rastilav Balheda, Christopher Twelves
Simon J. Harrison, Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Grant A. McArthur, John K. C. Lim, Sean O’Brien, David M. Ryckman, Grace I Yu, Emma Link, Carrie Donohoe, Alicia Snowden, Narmatha Kuru, Ross D. Hannan
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Grant A. McArthur, J.K.C. Lim, Sean O’Brien, David M. Ryckman, Grace I Yu, Emma Link, Carrie Donohoe, Austyn Snowden, Ross D. Hannan, Simon J. Harrison
Daniel Shao-Weng Tan, Herlinde Dumez, David Olmos, Shahneen Sandhu, Ann Hoeben, Andrew Stephens, Srinivasu Poondru, Richard Gedrich, S.B. Kaye, Patrick Schöffski
Discussion(0)
No comments yet. Be the first to comment.